- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
This study is testing a new tablet, AP1189, for people recently diagnosed with rheumatoid arthritis who haven't tried other strong medicines yet. It aims to see how well different doses of AP1189 lower inflammation and improve symptoms when taken with another common arthritis medicine.
For: Rheumatoid ArthritisBulgaria · Czechia · Poland - AuthorisedTherapeutic exploratory (Phase II)
A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid
This study is looking into a new tablet called AP1189 for people with polymyalgia rheumatica (PMR) who are doing well on their current steroid medication. Researchers want to see if this new tablet, taken daily for 12 weeks, is safe and can help patients stay well without steroids.
For: Polymyalgia rheumaticaDenmark